COMPANY INFO
MicroTransponder, Inc. was founded in 2007 by Jordan Curnes and Navzer Engineer, with additional founding contributions from Rosellini, Cauller, and Richard Weiner. The company is headquartered in Austin, Texas, and has approximately 138 employees. MicroTransponder develops the Paired Vagus Nerve Stimulation (Paired VNS™) platform, including the FDA-approved Vivistim® System for post-stroke upper limb impairment, aimed at improving quality of life for patients with chronic neurological conditions. It operates in the medical equipment manufacturing industry, focusing on neurostimulation devices for neurological disease treatment.
MicroTransponder Inc. was founded in 2007 by Jordan Curnes and Navzer Engineer, along with key contributions from Rosellini, Cauller, and Richard Weiner. Headquartered in Austin, Texas, MicroTransponder Inc. operates in the therapeutic devices industry, specifically focusing on neurostimulation devices for treating chronic neurological diseases. The company’s FDA-approved Vivistim® System, part of its Paired Vagus Nerve Stimulation (Paired VNS™) platform, is designed to support rehabilitation for post-stroke upper limb impairment, with the aim of substantially improving the quality of life for patients.
MicroTransponder Inc. funding has steadily accelerated since its inception, raising approximately $207 million across 20 funding rounds. The company’s funding strategy has encompassed a mix of early-stage venture capital, late-stage rounds, debt financing, and grants. Major milestones include a Series E round for scaling up operations and market presence, and a Series F round supporting the commercialization of innovative treatments for stroke recovery. MicroTransponder Inc. investors encompass top-tier venture capital firms and strategic healthcare investors, highlighting broad industry confidence and significant interest in the company’s mission to revolutionize neurological recovery.
The most recent Series F round, led by USVP, raised $65 million. This funding is dedicated to supporting the commercialization and wider adoption of the Vivistim stroke therapy system, aiming to accelerate market penetration and improve patient access.
The Series E round, also led by USVP, secured $73 million. The capital was used primarily for scaling operations, market expansion, and advancing research and development efforts to reach more patients in need of MicroTransponder’s neurostimulation solutions.
MicroTransponder Inc. secured $5.75 million in debt financing to reinforce company operations during a key phase of growth and technology development.
Raised $11.6 million in Series C funding to support product development, launch preparations, and the progression of pivotal clinical trials.
An additional $5.53 million in Series C funding was used to continue advancing development activities, clinical studies, and therapeutic validation.
USVP is a prominent Silicon Valley venture capital firm that has led multiple MicroTransponder Inc. funding rounds, including Series E and Series F. USVP’s repeated backing highlights its confidence in MicroTransponder Inc. investment potential and strategic vision.
Osage University Partners is a venture capital fund investing in startups commercializing university research. Their participation underscores the innovative scientific base of MicroTransponder Inc.
Green Park & Golf Ventures focuses on early-stage healthcare innovation. As an investor, they fostered MicroTransponder Inc.’s early growth and technology development.
Gilde Healthcare is a leading European specialist investor in healthcare innovation. Their involvement strengthens MicroTransponder Inc. fundraising and global market expansion efforts.
Longitude Capital is a major venture capital firm specializing in healthcare. Their investment supports MicroTransponder Inc. funding rounds and continued innovation.
Backed by GlaxoSmithKline, Action Potential Venture Capital invests in pioneering bioelectronic medicine. Their support aligns with MicroTransponder Inc.’s vision for neuromodulation therapies.
MedTech Innovator is an accelerator and venture funding platform for medical device companies, contributing strategic resources and investment to enhance MicroTransponder Inc. development trajectory.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching MicroTransponder Inc. funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.